发明名称 |
Sustained-release formulations of topiramate |
摘要 |
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. |
申请公布号 |
US8889191(B2) |
申请公布日期 |
2014.11.18 |
申请号 |
US201012926936 |
申请日期 |
2010.12.17 |
申请人 |
Supernus Pharmaceuticals, Inc. |
发明人 |
Liang Likan;Wang Hua;Bhatt Padmanabh P.;Vieira Michael L. |
分类号 |
A61K9/16;A61K9/24;A61K9/50;A61K31/357;A61K47/48;B82Y5/00 |
主分类号 |
A61K9/16 |
代理机构 |
Foley & Lardner LLP |
代理人 |
Foley & Lardner LLP ;Talapatra Sunit |
主权项 |
1. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to said subject in need thereof a therapeutically effective amount of a sustained release formulation of 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate (topiramate), wherein all of the topiramate is released in a continuous manner from the formulation, wherein at least 85% by weight of the total topiramate in the formulation is contained in an extended release (XR) component comprising at least two populations of beads coated with a release controlling coating and each having its own rate of release, and wherein at least one of the at least two XR populations releases 80% of the topiramate contained therein in vitro in not more than 4 hours. |
地址 |
Rockville MD US |